These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6662064)

  • 1. [Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency].
    Kettner W; Banditt P; Walther H
    Dtsch Z Verdau Stoffwechselkr; 1983; 43(6):255-66. PubMed ID: 6662064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of histamine H2 receptor blockers on hepatic elimination of drugs].
    Kettner W; Schröter U; Banditt P; Walther H
    Z Gesamte Inn Med; 1985 Feb; 40(4):96-8. PubMed ID: 4002755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life].
    Uhlig H; Damrau J; Skölziger R
    Z Gesamte Hyg; 1989 Feb; 35(2):82-4. PubMed ID: 2741499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
    Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
    Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine pharmacokinetics in the pregnant rat.
    Dean M; O'Donnell L; Penglis S; Stock B
    Drug Metab Dispos; 1980; 8(4):265-7. PubMed ID: 6105062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
    Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
    Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monthly variations in the clearance of antipyrine in the rat.
    Bélanger PM; Doré F; Labrecque G
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):53-65. PubMed ID: 6505390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of age on antipyrine metabolism in patients with gastric cancer.
    Higuchi T; Nakamura T; Uchino H
    J Natl Cancer Inst; 1980 Nov; 65(5):897-900. PubMed ID: 6933259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.